The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality
Purpose: This study investigates an intravitreal dexamethasone implant and its efficacy and complications in patients with diabetic macular edema (DME). Materials and Methods: This was a prospective, interventional study involving 30 eyes of 20 patients with DME. Patients' eyes with DME which w...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
| Series: | Kerala Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.kjophthal.com/article.asp?issn=0976-6677;year=2023;volume=35;issue=3;spage=297;epage=300;aulast=Chaudhary |
| _version_ | 1797231769108348928 |
|---|---|
| author | Shailender Kumar Chaudhary Nabeel Firoz Saloni Gupta Omprakash Anand Sahil Agrawal |
| author_facet | Shailender Kumar Chaudhary Nabeel Firoz Saloni Gupta Omprakash Anand Sahil Agrawal |
| author_sort | Shailender Kumar Chaudhary |
| collection | DOAJ |
| description | Purpose: This study investigates an intravitreal dexamethasone implant and its efficacy and complications in patients with diabetic macular edema (DME). Materials and Methods: This was a prospective, interventional study involving 30 eyes of 20 patients with DME. Patients' eyes with DME which were pseudophakic with a visual acuity of 6/12 or less and a central macular thickness (CMT) of 300 microns or more on optical coherence tomography were included. Primary efficacy variables were best-corrected visual acuity (BCVA), CMT, and intraocular pressure (IOP), noted at baseline. The patients were followed up and parameters noted at 1 week, 1 month, and 3 months following the implant into the vitreous cavity. Results: Eyes receiving the implant had a significant improvement (P < 0.001) in BCVA and gained a mean of 6.10 letters on the Snellen chart over the 3-month period. Furthermore, there was a significant reduction in CMT in the eyes receiving the implant. The mean increase in IOP over the 3-month follow-up, although statistically significant, was well within the normal physiological range. Conclusion: The study concluded that intravitreal dexamethasone implant is an effective treatment for DME, and it has a statistically significant and clinically meaningful effect on BCVA and CMT. |
| first_indexed | 2024-04-24T15:49:38Z |
| format | Article |
| id | doaj.art-cd2312de7afe465a9076596f5efec336 |
| institution | Directory Open Access Journal |
| issn | 0976-6677 |
| language | English |
| last_indexed | 2024-04-24T15:49:38Z |
| publishDate | 2023-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Kerala Journal of Ophthalmology |
| spelling | doaj.art-cd2312de7afe465a9076596f5efec3362024-04-01T12:58:19ZengWolters Kluwer Medknow PublicationsKerala Journal of Ophthalmology0976-66772023-01-0135329730010.4103/kjo.kjo_212_21The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modalityShailender Kumar ChaudharyNabeel FirozSaloni GuptaOmprakash AnandSahil AgrawalPurpose: This study investigates an intravitreal dexamethasone implant and its efficacy and complications in patients with diabetic macular edema (DME). Materials and Methods: This was a prospective, interventional study involving 30 eyes of 20 patients with DME. Patients' eyes with DME which were pseudophakic with a visual acuity of 6/12 or less and a central macular thickness (CMT) of 300 microns or more on optical coherence tomography were included. Primary efficacy variables were best-corrected visual acuity (BCVA), CMT, and intraocular pressure (IOP), noted at baseline. The patients were followed up and parameters noted at 1 week, 1 month, and 3 months following the implant into the vitreous cavity. Results: Eyes receiving the implant had a significant improvement (P < 0.001) in BCVA and gained a mean of 6.10 letters on the Snellen chart over the 3-month period. Furthermore, there was a significant reduction in CMT in the eyes receiving the implant. The mean increase in IOP over the 3-month follow-up, although statistically significant, was well within the normal physiological range. Conclusion: The study concluded that intravitreal dexamethasone implant is an effective treatment for DME, and it has a statistically significant and clinically meaningful effect on BCVA and CMT.http://www.kjophthal.com/article.asp?issn=0976-6677;year=2023;volume=35;issue=3;spage=297;epage=300;aulast=Chaudharydexamethasone implantdiabetic macular edemaintravitreal implantsteroid implant |
| spellingShingle | Shailender Kumar Chaudhary Nabeel Firoz Saloni Gupta Omprakash Anand Sahil Agrawal The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality Kerala Journal of Ophthalmology dexamethasone implant diabetic macular edema intravitreal implant steroid implant |
| title | The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality |
| title_full | The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality |
| title_fullStr | The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality |
| title_full_unstemmed | The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality |
| title_short | The efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema – Novel use as a primary treatment modality |
| title_sort | efficacy and complication of intravitreal dexamethasone implant in diabetic macular edema novel use as a primary treatment modality |
| topic | dexamethasone implant diabetic macular edema intravitreal implant steroid implant |
| url | http://www.kjophthal.com/article.asp?issn=0976-6677;year=2023;volume=35;issue=3;spage=297;epage=300;aulast=Chaudhary |
| work_keys_str_mv | AT shailenderkumarchaudhary theefficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT nabeelfiroz theefficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT salonigupta theefficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT omprakashanand theefficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT sahilagrawal theefficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT shailenderkumarchaudhary efficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT nabeelfiroz efficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT salonigupta efficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT omprakashanand efficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality AT sahilagrawal efficacyandcomplicationofintravitrealdexamethasoneimplantindiabeticmacularedemanoveluseasaprimarytreatmentmodality |